Chief executive of Shanghai Henlius Biotech
Appears in 1 story
Leading company's push into U.S. market
A randomized U.S. trial in extensive-stage small cell lung cancer found patients on Henlius' serplulimab lived a median 12.4 months, versus 10.2 months for Genentech's atezolizumab. The 201-patient study was a bridging trial designed to test whether global evidence for serplulimab holds in a U.S. population.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
